Related Experiment Video
Updated: May 25, 2026
09:19
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Prioritization in comparative effectiveness research: the CANCERGEN Experience.
Rahber Thariani1, William Wong, Josh J Carlson
1Department of Pharmacy, University of Washington, Seattle, WA 98195, USA.
Medical Care
|January 26, 2012
Summary
Prioritizing genomic tests for cancer research is feasible using a diverse stakeholder group. This approach identified top genomic tests for lung and breast cancer, guiding future comparative effectiveness research.
Area of Science:
- Oncology
- Genomic Medicine
- Health Services Research
Background:
- Stakeholder input is crucial for prioritizing research in comparative effectiveness.
- Genomic testing in cancer presents opportunities to refine research prioritization due to rapid advancements and patient outcome impacts.
Purpose of the Study:
- To develop and pilot a stakeholder-informed method for prioritizing genomic tests for future research.
- Collaboration with the SWOG ( = ) cancer clinical trials consortium was central to this effort.
Main Methods:
- A landscape analysis identified oncology genomic tests through systematic searches and expert consultations.
- A diverse stakeholder group, including patient advocates, payers, and clinicians, was convened.
- Stakeholders identified prioritization domains and ranked genomic tests through multiple voting rounds.
Main Results:
- Nine domains for research prioritization were established with stakeholder input.
- Six clinically valid genomic tests were presented to the stakeholder group.
- Top priorities included ERCC1 and EGFR tests for lung cancer, and CEA/CA15-3/CA27.29 for breast cancer.
Conclusions:
- A diverse stakeholder group can effectively inform research prioritization in a timely and pragmatic manner.
- Further research is needed to optimize search strategies, stakeholder composition, and integration with existing prioritization frameworks.
Related Concept Videos
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
01:20Comparing the Survival Analysis of Two or More Groups
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...